Skip to main content

Advertisement

SpringerLink
Log in

Safety and Efficacy of a Saquinavir-Containing Antiretroviral Regimen in Previously ART-Naïve or Pretreated but Protease Inhibitor-Naïve HIV-Positive Patients

  • Clinical and Epidemiological Study
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Background:

The RAINBOW survey is a multinational observational study assessing the tolerability and efficacy of ritonavir-boosted saquinavir (SQV/r), using the 500-mg filmcoated SQV formulation, in routine clinical practice. This analysis presents data from the German subgroup of antiretroviral therapy (ART)-naïve and pretreated but protease inhibitor (PI)-naïve patients.

Methods:

This was a multicenter, prospective, open-label, 48-week observational cohort study. Tolerability assessments included changes in liver enzymes and lipid levels from baseline to week 48. Efficacy assessments included changes in the proportion of patients with HIV-1 RNA <50 and <400 copies/ml, and changes in CD4 cell count from baseline to week 48.

Results:

The analysis included 275 ART-naïve and 179 pretreated but PI-naïve patients. The proportion of ART-naïve patients achieving <50 copies/ml by 48 weeks was 53.1% by intent-to-treat (ITT) analysis and 67.3% using last observation carried forward (LOCF) analysis. In pretreated but PInaïve patients, the proportions achieving <50 copies/ml by 48 weeks were 53.1% (ITT) and 70.4% (LOCF). The median increase in CD4 count at week 48 was +174 cells/mm3 (interquartile range [IQR] 86, 265) in the ART-naïve group and +100 cells/mm3 (IQR 0, 209) in the pretreated but PInaïve group (p < 0.01 for both; LOCF). Drug-related adverse events were reported in 7.6% of ART-naïve and 2.8% of pretreated but PI-naïve patients. Treatment with SQV/r was stopped in 21.5% of ART-naïve and 17.9% of pretreated but PI-naïve patients (due to side effects in 3.3% and 2.8%, respectively). There were no clinically relevant changes in liver enzyme levels. Overall, the total cholesterol, triglyceride, low-density lipoprotein, and high-density lipoprotein levels increased to week 48, although the levels remained within normal ranges in the majority of patients.

Conclusions:

The results of this observational cohort study of treatment with the 500-mg tablet formulation of SQV are consistent with high efficacy and tolerability results seen in controlled studies of SQV/r. This analysis confirms that SQV/r is effective and well tolerated in ART-naïve and pretreated but PI-naïve patients in ‘real-world’ clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, Francioli P, D’Arminio Monforte A, Fox Z, Lundgren JD, EuroSIDA study group: Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663–1671.

    Article  CAS  PubMed  Google Scholar 

  2. Hariri S, McKenna MT: Epidemiology of human immunodeficiency virus in the United States. Clin Microbiol Rev 2007; 20: 478–488.

    Article  PubMed  Google Scholar 

  3. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA, International AIDS Society-USA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555–570.

    Article  CAS  PubMed  Google Scholar 

  4. Bittner B, Riek M, Holmes B, Grange S: Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther 2005; 10: 803–810.

    CAS  PubMed  Google Scholar 

  5. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357–366.

    Article  CAS  PubMed  Google Scholar 

  6. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21–30.

    CAS  PubMed  Google Scholar 

  7. Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, Macarthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB: Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008; 22: 75–82.

    Article  CAS  PubMed  Google Scholar 

  8. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner JS: The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009; 50: 529–536.

    Article  CAS  PubMed  Google Scholar 

  9. Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD, MaxCmin2 Trial Group: A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther 2005; 10: 735–743.

    CAS  PubMed  Google Scholar 

  10. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B, Staccato Thailand Study Group: Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008; 13: 375–380.

    CAS  PubMed  Google Scholar 

  11. Walmsley S, Avihingsanon A, Slim J, Ward DJ, Ruxrungtham K, Brunetta J, Bredeek UF, Jayaweera D, Guittari CJ, Larson P, Schutz M, Raffi F: Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009; 50: 367–374.

    Article  PubMed  Google Scholar 

  12. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD, MaxCmin1 Trial Group: Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 2003; 188: 635–642.

    Article  CAS  PubMed  Google Scholar 

  13. Casado JL, Sabido R, Perez-Elías MJ, Antela A, Oliva J, Dronda F, Mejía B, Fortún J: Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients. Antivir Ther 1999; 4: 157–161.

    CAS  PubMed  Google Scholar 

  14. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30: 105–110.

    Article  PubMed  Google Scholar 

  15. Le Moing V, Chêne G, Carrieri MP, Alioum A, Brun-Vézinet F, Piroth L, Cassuto JP, Moatti JP, Raffi F, Leport C, Aproco Study Group: Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16: 21–29.

    Article  PubMed  Google Scholar 

  16. Raboud JM, Harris M, Rae S, Montaner JS: Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med 2002; 3: 118–124.

    Article  CAS  PubMed  Google Scholar 

  17. Autar RS, Boffito M, Hassink E, Wit FW, Ananworanich J, Siangphoe U, Pozniak A, Cooper DA, Phanuphak P, Lange JM, Ruxrungtham K, Burger DM: Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005; 56: 908–913.

    Article  CAS  PubMed  Google Scholar 

  18. Calza L, Manfredi R, Chiodo F: Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 10–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Practice Center Blondelstrasse (PZB), Blondelstr. 9, 52062, Aachen, Germany

    H. Knechten

  2. Clinic of the Johann-Wolfgang-Goethe-University, Frankfurt, Germany

    C. Stephan

  3. Practice Drs. F.A. Mosthaf/M. Procaccianti/K. Zutavern-Bechtold, Karlsruhe, Germany

    F. A. Mosthaf

  4. Medical Care Center (MVZ) Karlsplatz, HIV Research and Clinical Care Center, Munich, Germany

    H. Jaeger

  5. Infektiologikum Frankfurt, Frankfurt a.M., Germany

    T. Lutz

  6. Practice Drs. S. Dupke/A. Carganico/A. Baumgarten, Berlin, Germany

    A. Cargnico

  7. Institute for Interdisciplinary Medicine, Hamburg, Germany

    A. Stoehr

  8. Practice Drs. S. Koeppe/P. Kreckel, Berlin, Germany

    S. Koeppe

  9. Medical Care Center (MVZ) — Physicians Forum Seestrasse, Drs. C. Mayr/PD W. Schmidt, Berlin, Germany

    C. Mayr

  10. Medical Center for Infectious Diseases Hamburg, Hamburg, Germany

    K. Schewe

  11. MUC Research, Munich, Germany

    E. Wolf

  12. Roche Pharma AG, Grenzach-Wyhlen, Germany

    E. Wellmann

  13. Roche Pharma AG, Grenzach-Wyhlen, Germany

    A. Tappe

Authors
  1. H. Knechten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Stephan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. A. Mosthaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Jaeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Cargnico
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Stoehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Koeppe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Mayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K. Schewe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E. Wellmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. Tappe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Knechten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knechten, H., Stephan, C., Mosthaf, F.A. et al. Safety and Efficacy of a Saquinavir-Containing Antiretroviral Regimen in Previously ART-Naïve or Pretreated but Protease Inhibitor-Naïve HIV-Positive Patients. Infection 38, 108–116 (2010). https://doi.org/10.1007/s15010-009-9249-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-009-9249-x

Keywords

Search

Navigation